Urinary Tract Stenting Market 2016-2023 Industry Size, Shares, Research Trends

Urine is normally carried from the kidneys to the bladder through long, narrow, muscular tubes called ureters. The passage of urine may become difficult if the ureter becomes obstructed due to conditions such as tumors, infections, kidney stone, etc. For such conditions, the physicians place an artificial tube, known as ureteral stent, intended to restore the flow of the bladder. Aging is the most common factor that leads to several types of urology diseases. The global aging population is a direct indication of the possible rise in the patients suffering with urological diseases. With the increasing conditions that obstruct the flow of urine, the use of urological stents have become the most fundamental and valuable technique in the urological practice.

Obtain Report Details: http://www.transparencymarketresearch.com/urinary-tract-stenting-market.html

A ureteral stent is specially designed a soft tube 10-12 inches in length that is placed in the ureter for draining urine from the kidney to the urinary bladder. These stents are coiled at both the end to stay in place in the urinary system and therefore also known as JJ stent, pig-tail stent of double J stent. Normally a person can have ureteral stents for not more than 3 to 6 months. If left for longer duration, there is a possibility of stone formation which makes removal of stents difficult. If a patient is required to have stent for a longer duration, he must be admitted in the hospital for stent change. This is a serious limitation for the usage ureteral stent. Several companies operating in the market are trying to overcome the issue of biofilm formation and mineralogical encrustation. Furthermore, there are ongoing research activities in the global urinary tract stenting market to modify the design, discovering novel stent coating and the basic composition materials of the stent. Usage of metal stents in urology is being recommended by some physicians which have not yet become a widespread practice. Some of the advancements required for the industry include anti-body coated stents, nanotube coating, radioactive stents, and absorbable magnesium metal stent. The successful trials of the technologies have a potential to drastically change the existing market dynamics in the global urinary stenting market.

The global market for urinary tract stenting can be segmented on the basis of application of urology stents into kidney stones treatment. The major segments in which urological stents are used include procedures such as lithotripsy, ureteroscopy, ureteroenoscopy, and percutaneous nephrolithotomy. Based on the procedures of removing the obstruction in the ureter, the market can be segmented into ureteral stenting, prostate stenting and urethral stenting.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11072

Based on the geography, the global urinary tract stenting market is segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. More than 2 million people in the U.S. are annually diagnosed for the presence of kidney stone. The number of people suffering from similar diseases is even higher in the Asia-Pacific and Rest of the World. The rising number of kidney stone patients in the world is expected to increase the number of treatment procedures at a faster rate than before eventually increasing the demand for the urinary tract stents. As the economic conditions in the emerging nations such as China, India, and Brazil are expected to improve in the near future, most of the market growth will be fuelled by demand from these countries.

Some of the key companies operating in the global urinary tract stenting market include Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical, Inc., and Medline Industries, Inc., Pnn Medical A/S, and Allium Medical Solutions Ltd.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Hemoglobinopathies Market: Detailed Analysis of Market Structure from 2016 to 2024

Global Hemoglobinopathies Market

The U.S. National Library of Medicine defines hemoglobinopathy as a group of disorders passed down from one generation to another that are characterized by an abnormal structure or production of the hemoglobin molecule. Hemoglobinopathy disorders include sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and various forms of thalassaemia. The growing prevalence of hemoglobinopathy disorders, particularly sickle cell anemia, has boosted the growth of the global hemoglobinopathies market.

Though the prevalence of hemoglobinopathies is high across under-developed economies, including countries in Southeast Asia and the Sub-Saharan region, the global hemoglobinopathies market is expected to grow across developed and developing economies in North America and Asia Pacific, respectively, due to better health care infrastructure. The introduction of advanced diagnostics and therapeutics will likely boost the growth of the market in the coming years. Genetic testing, blood testing, pre-implantation genetic diagnosis, prenatal genetic testing, and hemoglobin electrophoresis are some of the key diagnostics for identifying hemoglobinopathies disorders. Iron chelation therapy, blood transfusion, hydroxyurea, and bone marrow transplant are the common therapies available in the market. Research and development activities and regulatory support are shaping the future of the global hemoglobinopathies market.

Obtain Report Details: http://www.transparencymarketresearch.com/hemoglobinopathies-market.html

Global Hemoglobinopathies Market: Overview

Among various hemoglobinopathy disorders, sickle cell anemia is the most common inherited blood disease. According to the World Health Organization (WHO), around 5% of the world’s population carries trait genes for hemoglobinopathy disorders such as thalassaemia and sickle cell anemia. While sickle cell anemia is most common across Africa, various forms of thalassaemia are prevalent in the Middle East, the Mediterranean basin, and Asia. In sickle cell disease, the half-moon shape of red blood cells causes poor blood oxygen levels and blood vessel blockages. This leads to anemia among the patients.

The rapid rise in the number of people affected by the disease has led governments and regulatory authorities to initiate awareness programs to decrease hemoglobinopathy-related mortality rates. For example, in 2010, the Centers for Disease Control and Prevention (CDC) started the Thalassaemia Data Collection Project and Blood Safety Monitoring. All these factors are expected to positively impact the growth of the global hemoglobinopathies market.

Further, the increased awareness about genetic testing for diagnosis of sickle cell anemia and other hemoglobinopathy disorders is anticipated to contribute significantly toward the growth of the market in the near future. Genetic testing has emerged as the most cost-effective strategy to reduce the prevalence of hemoglobinopathy disorders.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10676

Global Hemoglobinopathies Market: Region-wise Outlook

The global hemoglobinopathies market has been segmented into four key regions: Asia Pacific, Europe, North America, and Rest of the World. Sickle cell anemia is most common in Central and West Africa where about 25% of the population has sickle cell trait and around 1%-2% of all babies are born with a form of the disease. In North America, particularly in the U.S., where the population is estimated to be over 270 million, around 1,000 babies are born with sickle cell disease every year. The growing prevalence of various hemoglobinopathy disorders, along with a high level of awareness about hemoglobinopathy-related genetic testing has propelled the growth of the hemoglobinopathies market in North America. However, in the coming years, improving health care infrastructure in Asia Pacific and introduction of low-cost diagnostic alternatives are projected to boost the growth of the market in the region.




The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Sexually Transmitted Disease Testing Market: their impact and future predictions

Global Sexually Transmitted Disease Testing Market

Sexually transmitted diseases, also referred to as venereal diseases, are infections transmitted through sexual contact and are caused by viruses, bacteria, and parasites. These infections usually do not show any symptoms. Medically, when symptoms are diagnosed through various tests, a patient is said to be suffering from sexually transmitted disease or STD. Apart from sexual contact, STDs can in some cases also be transmitted through childbirth, breastfeeding, and shared usage of needles. Gonorrhea, HIV, HPV, chlamydia, and syphilis are the common types of STDs. According to data released by the U.S. Centers for Disease Control and Prevention in 2014, there has been an increase in the reported cases of STDs across the U.S. for the first time since 2006.

Rise in incidences of unprotected sex has led to an increase in the prevalence of sexually transmitted diseases, thereby propelling the demand from the global sexually transmitted disease testing market. STD testing is usually advised by physicians even if a person does not show symptoms but has had unprotected sex. There are various types of STD diagnostics available in the market such as viral load monitoring, genotyping, immunoassays, and molecular diagnostic.

Obtain Report Details: http://www.transparencymarketresearch.com/sexually-transmitted-disease-diagnostic.html

Global Sexually Transmitted Disease Testing Market: Overview

Lack of awareness about sexually transmitted diseases and the rising incidences of unprotected sex have majorly contributed to the growing prevalence of sexually transmitted diseases. The global sexually transmitted disease testing market has been boosted by the high number of patients suffering from STDs, especially in the age group of 15 years to 24 years. In fact, this age group is the most vulnerable to STDs even though it is relatively a small portion of the sexually active population.
Recommendations from various regulatory authorities for annual STD screening for sexually active men and women are expected to further fuel the demand for STD testing. STD screening services are now widely covered under health care services and are likely to augment the growth of the global STD testing market. For example, plans under the U.S. Affordable Care Act offer coverage for recommended STD screening services without cost-sharing. Regulatory authorities such as the World Health Organization have outlined strategies for the prevention and control of STDs. Research activities are being carried out to understand the growing prevalence of STDs, particularly Syphilis, among gay and bisexual men. All of these factors are anticipated to drive the growth of the global sexually transmitted diseases testing market.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1207

Global Sexually Transmitted Disease Testing Market: Region-wise Outlook

The global sexually transmitted disease testing market has been segmented into four key regions: Asia Pacific, North America, Europe, and Rest of the World. In North America, a reported rise in the number of people affected with STDs such as gonorrhea, chlamydia, and syphilis has fuelled the demand for sexually transmitted disease testing. Favorable government policies are also expected to boost the demand from the regional market. Recently, the outbreak of Zika virus and the possibility of the transmission of Zika virus through sexual contact have led authorities in countries in Africa and South America to recommend Zika virus testing.

Prominent players in the global sexually transmitted disease testing market include Bayer AG, Merck and Company Inc., Abbott Laboratories, and Home Access Health Inc.

Medical Billing Outsourcing Market Trends and Forecast up to 2023

The global medical billing outsourcing market has risen rapidly in recent years due to the rising use of IT resources in the healthcare sector and the steady government support for the same. Increasing healthcare expenditure in developed regions has led to consistent progress of the sector, enabling widespread adoption of advanced technological resources such as medical billing outsourcing. With the increasing availability of IT resources such as medical billing outsourcing, many medical institutions have opted to focus on healthcare dispensation, while third-party service providers have become important in several aspects of data storage and administration of healthcare entities.
Private funding for the healthcare sector has also been forthcoming in recent years, particularly in developing countries, which has helped ancillary components such as the medical billing outsourcing market.

Developing regions such as Asia Pacific are likely to be vital to the global medical billing outsourcing market in the coming years. The growing geriatric demographic in emerging countries in the region has been a vital driver for the healthcare sector, while it has also led to growing demand for ancillary support services such as medical billing outsourcing and electronic health records. Due to the steady investment in the healthcare sector in developing countries, the industrial web around healthcare is likely to grow, ensuring steady growth prospects for the medical billing outsourcing market. Several entities in the healthcare sector in developing regions lack the financial as well as technological resources to set up their own IT taskforce; this is likely to remain a key driver for the medical billing outsourcing market in the coming years.

Obtain Report Details: http://www.transparencymarketresearch.com/medical-billing-outsourcing-market.html

Global Medical Billing Outsourcing Market: Overview

As governments channel more funds into healthcare budgets, there is increasing pressure on healthcare systems to become more efficient so they can utilize these monetary allocations to the fullest. This benefits vendors in the global medical billing outsourcing market. While spending on healthcare in developed countries is rising on account of a substantial portion of the population cross the 65-year-threshold, developed countries are under pressure to improve their healthcare infrastructure, alleviate the inequality of healthcare in the private and public healthcare sectors, and a general increase in the number of chronic diseases reported.

Thus, the market for medical billing outsourcing will see steady growth, driven by the changing needs of healthcare providers, insurers, and other ancillary entities (both public and private). With a thrust on technology to streamline operations and manage transactions with greater transparency, the role of IT is becoming pivotal. As IT departments become necessary for the smooth operation of the healthcare industry as a whole, billing services, too, will likely be in demand.

The report touches upon the most pertinent factors at play in the global medical billing outsourcing market. It provides insight into the factors driving growth, the restraints, and the challenges, the most important market trends to watch out for, emerging opportunities for vendors in the market, and a SWOT analysis of the leading vendors. In addition to projections for the size of the overall market, the report forecasts the size and growth rate of each key market segment.

Global Medical Billing Outsourcing Market: Drivers and Opportunities

The global medical billing outsourcing market’s high-impact drivers will be the growing emphasis on compliance and risk management, the need to make processes efficient, and healthcare organizations’ stress on achieving the desired business goals. Greater control, transparency, and agility are the factors that clients look for in outsourcing models. Considering that medical billing outsourcing helps healthcare organizations meet critical goals such as maximizing ROI, helping the shrink the cash conversion cycle, and striking a balance between expenditures and earnings, vendors in this space face numerous opportunities.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10568

On account of all of these factors, the global medical billing outsourcing market is expected to report a high single digit growth rate over the review period of the report. However, the market could be restrained from reaching its full growth potential because of an ever-shifting and disparate regulatory landscape. Considering that some of the leading vendors in the global medical billing outsourcing market have a multinational presence, they are compelled to remain responsive to any changes in the regulatory scenario in each country. Likewise, data migration issues could stunt the market’s growth to some degree.

Global Medical Billing Outsourcing Market: Competitive Outlook

One of the most prominent changes that have shaped the global medical billing outsourcing market, as it stands today, is the growing perception among small and mid-sized healthcare firms that outsourcing helps cut operational costs and up efficiency. This trend, in turn, has been spurred by the fact that several healthcare organizations lack the investment capabilities to set up full-fledged IT departments of their own. It is important to note here that the initial cost of investment for the average billing management software is considerably high. Moreover, the outsourcing of billing services is a testament to the trust that a healthcare institution places in the vendor. Thus, the risk of vendors losing customers owing to a data breach or error in billing is high.

It is thus expected that companies in the medical billing outsourcing market will gain new customers in the form of small and medium-sized healthcare entities. Among the key vendors vying for a higher share in the global medical billing outsourcing market are Cognizant Technology Solutions, HCL Technologies, Accenture, and Genpact.

Retinal Implant Market: Business Challenges, Emerging Technologies & Competitive Landscape

Retinal implants are biomedical microchips designed to provide visual perception to people who have lost vision owing to degenerative eye diseases such as retinitis pigmentosa and age-related macular degeneration. These conditions lead to slow degeneration of photoreceptor cells in the retina of human eyes, leading to gradual loss of sight. However, some of the inner retinal neurons capable of transmitting signals from photoreceptors to the brain are preserved in most cases. Electrical stimulation of these remaining retinal neurons with the help of retinal implants, which are essentially microchips containing an array of light-sensitive diodes capable of converting incident light into electrical signals, can help reintroduce some vision to patients.

The report presents a detailed overview of the present state of the global retinal implants market and its crucial elements. It presents an analysis of the major factors that will influence the growth dynamics of the market and shape its future.

Obtain Report Details: http://www.transparencymarketresearch.com/retinal-implant-market.html

The data has been gathered with the help of primary and secondary research methodologies, and narrowed down with the help of industry-leading analytical methods. A definitive account of the regulatory scenario governing market decisions has also been included in the report, along with an analysis of the expected impact of the regulatory scenario on the market.

Retinal Implants Market: Present Scenario

Retinal implants were considered a medical impossibility until a few decades ago, primarily owing to the highly complex design of the human eye. However, some retinal implants have successfully cleared clinical trials and are being regularly used in clinics in developed regions such as Europe and North America.

Retinal implants such as Alpha IMS, developed by Germany-based Retina Implant AG, and Argus II, developed by U.S.-based Second Sight Medical Products, have received approval for large-scale marketing and are being successfully implanted in patients with retinitis pigmentosa.
With the rising number of successful outcomes of retinal implants and advancement in technologies, the global retinal implants market holds immense potential in helping patients with RP and several other degenerative conditions regain their sight.

Increase in the geriatric population and the consequent rise in the prevalence of degenerative conditions, technological advancements, and growing disposable income in developing countries will act as major drivers of the global retinal implant market in the next few years.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10313

Currently, retinal implants available in the market fall into two categories: epiretinal implants, which are fixed on the retina, and subretinal implants, which are fitted behind the retina. Retinal implants that can be fitted above the vascular choroid, called suprachoroidal implants, are also in clinical trials.

Retinal Implants Market: Challenges and Growth Opportunities

Biocompatibility and long-term stability of the material used for devising retinal implants are the major challenges in the global retinal implants market. These technical challenges have induced manufacturers and researchers to explore the use of new materials and combinations that will be most suitable for human eyes. This factor acts as a major restraint of the market as well as a major opportunity for medical device manufacturers and researchers.

Lack of medical reimbursement in developing and underdeveloped countries is a key issue restraining the global retinal implants market. In Germany, the Alpha IMS microchip is reimbursed by the statutory health insurance system, which insures 90% of the country’s population.

Complex surgery, difference in people’s biological response to foreign objects being placed inside their bodies, and high cost of procedures are the other major challenges faced by the global retinal implants market. Owing to the complex nature of implant surgeries, comprehensive training in the technology and technique and appropriate selection of patients is also a crucial factor governing the large-scale adoption of retinal implants. Dearth of trained professionals in several regions is limiting demand for retinal implants.

Continuous Renal Replacement Therapy Market size and key trends in terms of volume and value 2016-2024

Global CRRT Market: Overview

Acute kidney injury (AKI) or acute renal failure is a common complication in critically ill patients and is often associated with mortality and morbidity. Renal replacement therapies have witnessed significant technological advancements in the last two decades. A steady and positive evolution in the areas of hemodialysis (diffusion-based removal of solute) and hemofiltration (convection-based removal of water and solute), and consequently in the treatment of AKI is approached, and the introduction of new devices and techniques have made more efficient renal replacement therapies possible.

Continuous renal replacement therapy (CRRT) is a popular choice for the treatment of ICU patients with AKI, especially for hemodynamically unstable cases. CRRT involves solute removal from blood by either hemofiltration or hemodialysis, or a combination of both. CRRT is carried out for about 24 hours in an ICU, making it quite different from conventional renal replacement therapies that involve intermittent hemodialysis lasting from four to six hours or even less.

Obtain Report Details: http://www.transparencymarketresearch.com/continuous-renal-replacement-therapy-market.html

One of the major advantages of CRRT is the slower rate of removal of solute or fluid per unit time. Hence, CRRT is better suited than conventional therapies involving intermittent hydrolysis as many of the complications occurring are related to the rapid rate of removal or loss of solute and fluid. These clinical advantages of CRRT over other renal replacement therapies and the potential for higher survival rates (realized by several trials and surveys) have led to an increased demand for CRRTs in the past few years. Nephrologists are increasingly prescribing CRRT owing to its short- and long-term benefits and the adoption among patients is rising at a steady pace globally.
A complete analysis of the market’s regulatory scenario and competitive landscape has also been provided in the report, with detailed data regarding major rules, regulations and policies, and key vendors operating in the market.

Global CRRT Market: Key Drivers and Restraints

Rising global geriatric population, continuous increase in the number of ICU patients, growing preference of health care practitioners to the modality over conventional hemodialysis methods owing to the clinical benefits of CRRT, and technological advancements in the field of CRRT systems are the major factors driving the global CRRT market.

High cost of CRRT systems, dearth of trained staff for handling CRRT systems, stringent regulations in the developed regions, and unfavorable medical reimbursement policies in developing countries are holding back the market. The factors of high cost of these systems as well as the overall procedure involving CRRT systems and unfavorable medical reimbursement policies are especially affecting the large-scale adoption of CRRT systems in developing and under-developed countries.
Nevertheless, continuous rise in investments aimed at improving health care infrastructure and rising disposable incomes in major developing markets such as China, India, and Brazil are likely to open favorable growth avenues for the global CRRT market. The rising geriatric population in these countries has also led to an increase in demand for CRRT systems.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10298

Global CRRT Market: Competitive Outlook

The report provides details such as business profiles, revenues, SWOT analysis, Porter’s Five Forces Analysis, and recent technologic developments pertaining to the major companies in the global CRRT market. These include Baxter International, Bellco S.r.l., NxStage Medical, Inc., B. Braun Melsungen AG, and Asahi Kasei Medical Co., Ltd. The market is being defined by collaborations and partnerships. Companies strive to commercialize their CRRT portfolios to gain a larger share of the market.

The report also presents a comprehensive overview of the global CRRT market, analyzing the market positions of key market segments on a regional as well as global level with the help of qualitative and quantitative data. The report also includes a detailed account of all the major growth drivers, restraints, and trends that will have a significant influence on the overall development of the market during the forecast period.

Nucleic Acid Aptamers Market: Strategies & Insights, & Recent Developments

Global Nucleic Acid Aptamers Market: Overview

Aptamers are peptides or oligonucleotide molecules that bond with a specific target molecule. Nucleic acid aptamers are a special class of nucleic acid species created via rounds of in-vitro selection or SELEX (systematic evolution of ligands by exponential enrichment). Nucleic acid aptamers help in binding various molecular targets such as proteins, cells, tissues, and organisms. They also assist in molecular recognition of certain characters that fight antibodies and, as a result, are quickly emerging as a possible alternative to commonly used biomolecule, antibodies.
Nucleic acid aptamers are not only distinctly recognizable, they also offer other advantages over antibodies, such as the possibility to be synthesized completely in a test tube, desirable storage properties, and extremely little immunogenicity in therapeutic applications. Concurrently, the global market for nucleic acid aptamers is projected for a robust CAGR during the forecast period of 2016 to 2023.

Obtain Report Details: http://www.transparencymarketresearch.com/nucleic-acid-aptamers.html

The global nucleic acid aptamers market can be segmented on the basis of type of technology and application. Some of the most prominent technologies are oligonucleotide synthesis, bioinformatics and next generation sequencing, modified oligonucleotides, nanoparticles and quantum dot labels, surface plasmon resonance and biolayer inferometry. By application, the market can be categorized as diagnostics and therapeutics. The diagnostics segment is further classified as application in human clinical diagnostic assays, veterinary diagnostics, and environmental monitoring. The therapeutics market is segmented on the basis of the currently available aptamer drugs, drug delivery in cancer therapy, various conditions targeted by aptamer drugs, and use of aptamers in modification of surgical implants.

Global Nucleic Acid Aptamers Market: Trends and Opportunities

The application of aptamers in therapeutics, diagnostics, and research is on the rise as they exhibit enhanced effectiveness, which is driving the global market for nucleic acid aptamers. Favorable policies by several governments across the globe for conducting clinical trials and research is also encouraging market expansion. Another factor expected to positively impact the global market for nucleic acid aptamers is their low manufacturing cost, which makes them ideal for the treatment of common life-threatening diseases such as cancer, HIV/AIDS, and other autoimmune diseases. Additionally, patent expiration of SELEX open new opportunities for players.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1330

Conversely, unfavorable government regulations in European countries is expected to hinder the growth of the market for nucleic acid aptamers in the region. Moreover, the market is facing similar challenges in developing countries such as India and China, coupled with poor response from consumers due to ethical issues. This factor is curtailing the growth rate in the vastly populated Asia Pacific region. Lack of trained professionals is another restraining factor for the market.

Global Nucleic Acid Aptamers Market: Region-wise Outlook

Due to robust healthcare infrastructure, high adoption rate of new technology, and favorable government policies in the regional market for nucleic acid aptamers, North America currently dominates the demand and is expected to remain most lucrative during the forecast period. However, Asia Pacific is projected for healthy growth due to vast populations and increased government initiatives towards improving medical facilities.

Companies mentioned in the research report

Some of the prominent companies in the global market for nucleic acid aptamers are Araxis Kits, LLC, Aptamer Sciences, Inc., Aptagen, LLC, Envirologix, Inc., Cytogenix Inc., Mitsui & Co. Inc., and Quest Diagnostics.

Cell Freezing Media Market will explore robust size & growth during 2016-2024

Cell freezing or cryopreservation is the method of freezing tissues and cells at low temperatures to keep the biological material metabolically inert and genetically stable, and to reduce ice crystal formation. Ice crystals are smaller crystals of ice that form when the temperature is quite low and these can disrupt the cell membrane of the cell or tissue and can lead to death of cell. Cryopreservation is done to exchange some of the water cells with other compounds to reduce crystal formation. For cell freezing, various types of media or serum are used. The most common substitutes are glycerol and DMSO (dimethyl sulfoxide). Glycerol and dimethyl sulfoxide are mixed into a solution with serum or media in which cells are sited and suspended in a liquid nitrogen freezer. As media starts to freeze, the concentration of salt outside the cells become greater than the cells, and water leave the cells to exchange by cryopreservative.

Obtain Report Details: http://www.transparencymarketresearch.com/cell-freezing-media-market.html

Cell freezing media commonly comprises a protein source, base medium, and a cryopreservative. Cryopreservatives are used to protect the cells from physical stress, mechanical and diminishes the water content inside the cells, and minimizing the development of cell death or celllysing ice crystals. The protein source also protects the cells from the stress linked with the freeze-thaw process. Cells are frozen gradually, at one degree Celsius per minute, using techniques and programmable coolers.
The cell freezing media market has been segmented based on type of media and end-user. In terms of type of media, the cell freezing media market has been categorized into Chinese hamster ovary (CHO) cell Media, hybridoma media, insect media and vaccine production media. Chinese hamster ovary cells are capable of harvesting various recombinant glycoproteins at great levels on a big scale and have potential in pharmaceutical research and development and in bioprocessing. Hybridoma media is used in the development of monoclonal antibodies in cell culture system. Insect media is used for development of genetically engineered cell lines to express therapeutically valuable recombinant proteins. Insect media is a rapidly growing segment as it has created major breakthrough in health care. The vaccine production media is of various types such as classic media and salts, additional vaccine media, cell line media, fetal bovine serum (FBS), and other animal sera.
In terms of end-user, the cell freezing media market has been segmented into biopharmaceutical companies, pharmaceutical companies, and academics and research. Biopharmaceutical companies is the fast growing segment of the cell freezing media market owing to increasing research in the segment. Cell freezing media are used in pharmaceutical medicines for drug screening, formation of regenerative medicine, etc.

In terms of region, the cell freezing media market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are projected to account for major share of the global cell freezing media market. Increasing research activities in North America and Europe for new drug development is anticipated to drive the cell freezing media market during the forecast period. Asia Pacific is the most progressive region for the cell freezing media market due to rising focus on bioprocessing and pharmaceutical research and development in countries such as Japan, China, and India.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20492

Increasing government initiatives for research in the pharmaceutical and biopharmaceutical segment is expected to fuel the growth of the cell freezing media market. Additionally, advantages of cell freezing for storage in drug development or in other programs are likely to fuel the growth of the market. However, high maintenance cost in storage procedure is the major factor that can hamper the growth of the market during the forecast period.

Major players in the cell freezing media market are Merck KGaA, Thermo Fisher Scientific, Inc., Nippon Genetics, Miltenyi Biotec, Mediatech, Inc., General Electric Company, BioLifeSolutions, Inc., HiMedia Laboratories, and PromoCell GmbH.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Ulnar Nerve Entrapment Market is Expected to Witness Highest Growth During 2017 - 2025

The global ulnar nerve entrapment market is prophesied by Transparency Market Research (TMR) to showcase a strong potential for a substantial growth in the foreseeable future. Bearing the title “Ulnar Nerve Entrapment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025,” a report by TMR prognosticates this growth to be fortified on the back of rising research and development investment made by pharmaceutical businesses. Furthermore, the introduction of novel technologies and products for treating ulnar nerve entrapment could hike up the demand in the market. Other factors such as elevating occurrences of vascular diseases are foreseen to positively impact the demand in the market.

Obtain Report Details: http://www.transparencymarketresearch.com/ulnar-nerve-entrapment-market.html

Conversely, there could be some factors impeding the growth of the world ulnar nerve entrapment market, such as restricted budget of small and medium-sized enterprises (SMEs) and long duration of treatments. Nevertheless, there could be opportunities springing up from the ignorance of the pain associated with the condition and high cost of surgery. Although the market for ulnar nerve entrapment could be in its emerging stage, vendors are expected to invite favorable prospects in the coming years.

Non-surgical and surgical could be two of the most popular treatments available in the world ulnar nerve entrapment market. Under non-surgical treatment, there could be more options, including splint and supporter devices, vitamin B6 supplement, non-steroidal anti-inflammatory drugs (NSAIDs), and medicines such as amitriptyline. The demand for ulnar nerve entrapment treatment could be projected to surge through key end users such as sports, chronic and acute care, ambulatory surgical clinics, and hospitals.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=27032

Out of all the important regions of the international ulnar nerve entrapment market, North America could take a leading position while riding on the business success in the U.S. The wild spread of chronic diseases and surging prevalence of other disorders are anticipated to be crucial factors improving the growth of the ulnar nerve entrapment market in the country. Having that mentioned, there could be other factors taking shape in the U.S. market, for instance, increasing research and development and invention of novel technologies. Asia Pacific, on the other hand, is envisaged to exhibit a faster growth in the market with a growing patient base and healthcare expanse in the limelight.

Some of the significant companies operating in the worldwide ulnar nerve entrapment market could be Amneal Pharmaceuticals LLC, Apotex, Inc., Teva Pharmaceutical Industries, Ltd., Alkem Laboratories, and Pfizer, Inc. With a view to secure a substantial share in the market, players are predicted to take to period launch of new products and variation in their existing products and services.

Orthopedic Implants Market: Current status and future trends

Orthopedic implant is a medical device used to replace damaged bone or missing joint to restore its function. It is surgically inserted into the body. These implants are usually biocompatible and made of stainless steel or titanium, with a coating of plastic which acts as artificial cartilage. Orthopedic implants are classified under class III category of medical devices. Large number of people are suffering from osteoporosis and osteoarthritis problems owing to changing lifestyle and lack of exercise and nutrition intake. Both prosthetic designs and biological factors influence the acceptability and performance of orthopedic implants.

Obtain Report Details: http://www.transparencymarketresearch.com/orthopedic-implants-market.html

Significant rise in the number of osteoarthritis patients due to increasing prevalence of diabetes, obesity, increased body mass index, low bone density, and aging population are the major drivers of the orthopedic implants market. Increase in number of sports related injuries and rising number of trauma cases due to road accidents also propel the orthopedic implants market. However, limited medical insurance coverage and stringent regulatory approval process act as major restraints of the market. Hypersensitivity, toxicity, post-surgery infections, and implant dislocation are the increasing concerns among patients. Widespread application of orthopedic implants in areas such as oncology, spine surgeries, and traumatology; use of minimally invasive surgeries for the treatment of orthopedic diseases, and rapidly growing 3D innovative technology with advanced imaging techniques to create precise orthopedic implants could be considered as opportunities in the orthopedic implants market.
Based on product type, the orthopedic implants market can be segmented into spinal implants, dental implants, trauma & carniomaxillofacial implants, reconstructive joint implants, orthobiologics, and others. The reconstructive joint implants segment holds the largest market share due to high number of knee replacement surgeries driven by rise in osteoarthritis and osteoporosis among the geriatric population. The spine implants segment is anticipated to witness significant growth in the next few years due to constant rise in sports related injuries, road accidents, and disc degenerative conditions.
In terms of biomaterial, the orthopedic implants market can be categorized into metallic biomaterials, polymer biomaterials, ceramic biomaterials, and natural biomaterials. The metallic biomaterials segment accounts for the largest market share due to rigidity imparted on the implants, minimal risk of infection, and compatibility with body tissues.

Based on device type, the orthopedic implants market can be segmented into internal fixation devices and external fixation devices (orthopedic rods/wire, orthopedic screws, orthopedic plates, fixation pins and orthopedic nails).

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26009

In terms of region, the orthopedic implants market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the market due to rising technological innovations and transition toward minimally invasive procedures. Asia Pacific is anticipated to witness significant growth due to increased medical tourism. However, the orthopedic implants market in Latin America is likely to be sluggish due to low income growth which in turn lowers health care expenditure.

Key players in the orthopedic implants market are Medtronic plc, The Orthopedic Implant Company, Zimmer Biomet Holdings, Inc., Wright Medical Group N.V., Aesculap Implant Systems, Stryker Corporation, DePuy Synthes, BioTek Instruments, Inc., Conmed Corporation, Smith and Nephew plc, Aesculap Implant Systems, Arthrocare Corporation, NuVasive, Inc., and Integra LifeSciences Holdings Corporation.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Renal Cell Carcinoma Market: Impact of Key Factors Influencing the Parent Industry

Renal cell carcinoma, also known as adenocarcinoma, refers to the cancer of kidneys in which malignant cells are found in the renal tubules. It commonly occurs in adults and the geriatric population. Among the types of kidney cancer, renal cell carcinoma is highly prevalent and accounts for 80–90% of the total cases as opposed transitional cell carcinoma which constitutes 5 -10% The renal cell carcinoma market is expected to develop at a decent rate due to the increased incidence reported worldwide. Surgical removal is not the singular solution, especially after the cancer has reached metastatic phase. Therapies with increased effectiveness and limited side-effects such as such as immunotherapy and targeted agents are required in such cases.

Obtain Report Details: http://www.transparencymarketresearch.com/renal-cell-carcinoma-market.html

Drivers of the renal cell carcinoma market include changing lifestyles, increased levels of smoking & tobacco consumption, misuse of certain painkillers, obesity, and the growing geriatric population. The rising incidence of renal cell carcinoma and comparative lack of availability of effective therapies available point toward the scope of this market. However, the high cost of the medicines and threat of generic entry may hinder the market. Chemotherapy is not effective in renal cell cancer and results in multiple side effects such as nausea & vomiting and weight & hair loss. It can also suppress production of new blood cells, leading to fatigue, anemia, easy bruising or bleeding, and increased risk of infection. Hence, chemotherapy is now replaced with targeted agents and immunotherapies.
The renal cell carcinoma market is segmented according to type of therapy into the following divisions: surgery, chemotherapy, biological therapy, hormone therapy, targeted agents, and radiation therapy. Among these, biological therapy and targeted agents are highly popular. The chemotherapy sector is further divided by therapeutic drug class into the following segments. RTK (Receptor Tyrosine Kinase) inhibitors, VEGF (Vascular Endothelial Growth Factor) inhibitors, mTOR (mammalian Target of Rapamycin) inhibitors, and TKI (Tyrosine Kinase Inhibitors). Sunitinib is commonly prescribed as it targets multiple receptors which, however may result in multiple side effects, thereby offering scope to emerging low cost drugs.

Geographically, the renal cell carcinoma market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe dominated the global market due to unhealthy lifestyles, obesity, and hypertension in these regions and excessive smoking in the U.S. Asia and South America exhibit minimal incidence of renal cell carcinoma. Rising awareness and disposable incomes are anticipated to propel the renal cell carcinoma market. Japan and Italy, known for their extensive geriatric population, are predicted to dominate the market. On the other hand, in Asia Pacific, the market is in its developmental phase due to the increasing capacity of individuals to afford high cost medicines and growing geriatric population. Rapid economic development in India, China, Singapore, and Malaysia been projected to motivate the renal cell carcinoma market. According to a study by NCBI named “Racial Disparity in Renal Cell Carcinoma Patient Survival according to Demographic and Clinical Characteristics” published in 2012, the African population runs a comparatively higher risk of developing renal cell carcinoma. Thus, countries with dense African population display potential for the development of renal cell carcinoma market.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25928

Key players in this market include Pfizer, Exelexis Inc., Eisai, GlaxoSmithKline plc. F. Hoffmann-La Roche AG, Novartis International AG, and Bayer AG. Pfizer is leading the market; however GlaxoSmithKline plc. and Novartis are extending their global presence with increased distribution channels.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Smart Cards in Health Care Market: Emerging Trends and New Technologies Research 2016 - 2024

A smart card is a small plastic card with an embedded integrated circuit (IC) chip. This integrated circuit (IC) chip is a microprocessor that makes the smart card suitable for different electronic applications. The chip on the card is used to store, manage, calculate, and safely access some personal valuable data or information when needed by a card reading machine or other system. Smart cards use encrypted algorithms for data management and are considered safer than magnetic strip cards. Smart cards are widely used to handle sensitive information such as identity, finances, and personal health information due to their added security features. Smart cards are also used in several key applications such as health care services, banking and financial corporations, entertainment, telecommunications, government authorities, and transportation.

Obtain Report Details: http://www.transparencymarketresearch.com/smart-cards-in-health-care-market.html

Smart cards in the health care sector have gained massive popularity in the last decade. This can be attributed to several value added features that smart card usage can offer to patients as well as providers. With the health care boom in the last few decades, maintenance of health data has become a necessity, yet tiring process in large facilities. Health care organizations globally are extensively using smart health cards that offer an extensive range of applications. Smart cards in health care can help enhance the security and confidentiality of patient data, maintain accurate patient identification across different facilities and geographies, provide secure access to emergency medical information, easy bill payment using the card for a financial transaction, reduce health care fraud, offer a secure medium for convenient medical records, and permit better compliance with government initiatives and instructions.

The global smart cards in health care market is anticipated to be driven by a number of factors such as growing demand for better patient data management systems and increasing inclination for electronic data management approaches. In addition, growing stress on patient data safety is expected to drive the market. Furthermore, increasing research and development activities by key players to develop new products is projected to boost market growth.

Based on products, the smart cards in health care market can be divide into contact-based smart cards, contactless smart cards, dual-interface smart cards, and hybrid smart cards. Contact-based smart cards comprise a gold chip that needs a smart card reader to access and interpret data, while contactless smart cards contain a microprocessor chip and an antenna coil that enables them to work faster than contact cards. Another key driver of the market is tamper-proof data storage. Advancements in product technology and rising awareness among the common people about the benefits of smart cards is also expected to increase demand in the near future.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18374

In terms of region, the smart cards in health care market can be segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America and Europe have been dominating the market due to high acceptance of digital mediums in the regions. According to a research study conducted by the Workgroup for Electronic Data Interchange (WEDI), smart cards usage in health care could decrease the error rate of mismatched patient data from 10% to 15% to as low as 2%. Additionally, new and advanced technology such as hybrid cards launched by various market players coupled with growing online campaign and acceptance of these products by customers is expected to drive the market. Developing nations in Asia Pacific are expected to witness the fastest growth during the forecast period. Growing patient pool, increased public awareness, and increasing affordability are the major drivers of the market in these geographies.

Some of the players in the smart cards in health care market are Atos SE, American Express Company, CardLogix Corporation, Giesecke & Devrient (G&D) GmbH, Gemalto NV, Infineon Technologies AG, INSIDE Secure SA, Oberthur Technologies SA, SCM Microsystems, and VeriFone Holdings, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Obesity Treatment Market Offering High-growth Opportunities for Market Players

Obesity is a disorder in which excess body fat gets accumulated to such extent that it may have negative effects on health. It occurs over time when people eat more calories than they utilize. The reasons for obesity can be medical problems, inactivity, genetics, family lifestyle, unhealthy diet, medications, age, and pregnancy. Being obese increases the risk of diabetes, heart disease, stroke, arthritis, and some type of cancers.

Obesity treatment basically incorporates a two-step process: assessment and management. Obesity assessment includes determination of the level of obesity and obesity management involves overall maintenance of body weight as well as the systematic weight loss programs.
Government initiatives to increase the awareness about fitness, technological advancements improving the compliance rates of surgeries, and aggressive marketing strategies to attract customers are some of the drivers for the growth of the obesity treatment market.

Obtain Report Details: http://www.transparencymarketresearch.com/obesity-treatment-market.html

Factors responsible for restraining the growth of the obesity treatment market are availability of low cost alternatives, high cost of customization, and post-surgical side effects.
The obesity treatment market is segmented based on lifestyle changes, surgical & implant devices, and medication therapy. Lifestyle changes involves dietary changes and exercise. The dietary segment held a significant share in 2015 and is expected to increase during the forecast period. The reasons for the projected growth of the segment might be low cost of therapy, increase in health consciousness among people, and acceptance of the fact that it is easier to lower calorie intake to a greater degree than to burn more calories through increased exercise.

The surgery & implant devices are further categorized into gastric bypass surgery, gastric balloon, gastric band, electrical stimulation system, and gastric emptying system. Gastric bypass surgery is a fast growing segment in the obesity treatment market owing to factors such as fast recovery time, improved psychological status, and improved longevity. The minimally invasive segment is expected to grow at a higher rate during the forecast period due to its reversible nature, rapid effect, and cost & time effectiveness. It basically involves employing the implant devices in gastric area, which minimizes the incidences of post-operative infections that arise from invasive procedures. It in turn shortens the hospital stays for patients.

In medication therapy, the individual (satiety) drug and combination drug therapy are the two major segments. The combination drug segment in the obesity treatment market captured a large share globally in 2015. It is mainly attributed to the synergistic effect of combined therapy in obesity treatment and rising prevalence of obesity. The satiety drug which provide a feeling of gastric fullness is a fast growing segment in the obesity treatment market. The major reason for the growth is its cost which is lower than that of the combination therapy.

Geographically, the obesity treatment market is segmented into North America, Europe, Asia Pacific, and rest of the world. In 2014, North America accounted for a significant share of the market owing to the rise in childhood obesity rates, strong government support and funding, growth in obese population, increase in membership for health clubs, lifestyle changes, and technological advancements in this region. North America is expected to maintain the level owing to heavy R&D investments deployed to develop rational and effective obesity treatment processes. Asia Pacific is estimated to grow at a high rate due to increase in demand for drugs, commercialization of minimally invasive surgical procedures, and rise in awareness about risks associated with obesity. Moreover, unhealthy diet and sedentary lifestyle are likely to increase the number of obese people during the forecast period.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18497

Key market players operating in the obesity treatment market include NutriSystem, Inc. (U.S.), Kellogg Company (U.S.), Ethicon, Inc. (U.S.), Atkins Nutritionals, Inc. (U.S.), Herbalife Ltd. (U.S.), Covidien plc (U.S.), Apollo Endosurgery (U.S.), Amer Sports (Finland), Johnson Health Technology, Ltd. (Taiwan), Cybex International (U.S.), Olympus Corporation (Japan), Brunswick Corporation (U.S.), and Technogym SpA (Italy). Increase in focus of the market players on gaining FDA approvals to launch new drugs and devices in the obesity treatment market propels the growth of the obesity treatment market exponentially during the forecast period.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Heart Attack Diagnostics Market: Industry Overview and Key Factors

Heart attack diagnosis is associated with intensive care of patients battling with life threatening conditions, which requires sophisticated invasive monitoring devices and life support systems. Heart attack (myocardial infarction) occurs due to reduced or total cut off of oxygenated blood supply to the heart muscle. It is one of the major causes of death observed worldwide and needs to be diagnosed rapidly and accurately. According to Centers for Diseases Control and Prevention, about 735,000 Americans suffer from heart attack every year. Occurrence of heart attacks is increasing in adults as well as in geriatric population across the globe due to unhealthy lifestyle habits, high cholesterol levels, high BMI, and growth in tobacco and alcohol consumption. The demand for heart attack diagnostic devices has increased owing to rise in need for continuous monitoring of individuals, accessibility for patient, changing lifestyle, higher investments in R&D, and technological advancement. Further, various international organizations and government across the globe are creating awareness about monitoring devices among the population.

Obtain Report Details: http://www.transparencymarketresearch.com/heart-attack-diagnostics-market.html

Several factors are responsible to propel the heart attack diagnostics market, but few factors are likely to continue to restrain the growth of the market in the near future such as the low Medicare reimbursements provided for the peripatetic cardiac outpatient telemetry electrocardiogram (ECG).
The heart attack diagnostics market can be segmented on the basis of test, end-user, and geography. In terms of test, the market can be divided into electrocardiogram (ECG), blood test, chest X-ray, echocardiogram, coronary catheterization (angiogram), exercise stress test, and magnetic resonance imaging (MRI). Among these, ECG has a wider application and contributes to tremendous growth of the market. End-user of this market includes hospitals, specialty clinics, and pathology among others.
In terms of geography, the heart attack diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of market revenue, North America is estimated to dominate the global heart attack diagnostics market owing to increased adoption of technologically advanced diagnostic equipment. The Asia Pacific market is projected to grow at a higher rate owing to high incidence of heart attacks and soaring death rates due to heart diseases.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17996

The heart attack diagnostics market is highly fragmented due to involvement of many recognized as well as emerging players in this market. Key players involved in the heart attack diagnostics market include Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories Inc., Siemens Healthcare Diagnostics, GE Healthcare, Life Sign LLC, Hitachi Medical Systems, and Schiller AG.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Allergy Diagnostics Market: An Overview of Growth Factors

The global allergy diagnostics market appears to be consolidated. The leading companies discussed in the report include Quest Diagnostics, Inc., Omega Diagnostics Group Plc, Thermo Fischer Scientific, Inc., Siemens Healthineers, bioMérieux SA, HAL Allergy Group, and Stallergenes Greer. Transparency Market Research (TMR) finds that the allergy diagnostics market is rife with heightened levels of competition among the companies, owing to the presence of local as well as international players. Dominant players have been adopting the fruitful strategy of collaborating with leading companies.

The market for allergy diagnostics is projected to expand substantially at a CAGR of 12.8%, achieving US$3.8 bn by the end of 2024, which was estimated to be worth US$1.3 bn in 2015.

Low Cost of Consumables to Position them as Leading Product Segment

This 197 page report gives readers a comprehensive overview of the allergy diagnostics market. Browse through 30 data tables and 83 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/allergy-diagnostics-market.html

Allergy diagnostic consumables was the leading product segment in 2015 and is expected to continue to hold its dominance in the market over the coming period. Reagents and pipettes are some examples of consumables that have grown popular on account of their lower costs and high volume. The segment is expected to attain a 50.1% share by the end of 2024, with a remarkable CAGR of 13.6% between 2016 and 2024.

North America is expected to emerge as the dominant regional market for allergy diagnostics. However, Asia Pacific is projected to emerge as a rapidly growing market, with a remarkable CAGR of 13.6% between 2016 and 2024.

High Level of Pollution to Drive Growth

Lack of exposure to allergic elements in childhood and high levels of hygiene maintenance, particularly in the western countries, has contributed towards a rise in the demand for allergy diagnostics. Furthermore, factors such as longer duration of pollen seasons, climatic changes, high levels of air pollution on account of industrial and traffic smoke, increased tobacco smoking, and prevalence of other allergens in the environment are driving the market for allergy diagnostics. Moreover, genetic factors, increased vulnerability to allergies, and rise in healthcare expenditure are also boosting market growth. High prevalence of asthma among global population is also responsible for the rising demand for allergy diagnostics.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving allergy diagnostics market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5147

An important concept related to the expansion of the allergy diagnostics market is the “hygiene hypothesis”. This hypothesis proposes that little or no exposure to infectious agents during childhood makes a person more vulnerable to allergies, on account of early restriction on the development of the immune system. This is more prevalent in western countries, where hygiene is given utmost importance. The U.S., New Zealand, the U.K., and Australia showed 20 times higher incidence of allergies as compared to other countries in 2013. This tendency has been driving the growth of allergy diagnostics market in the west.

Regulatory Policies Will Pose a Major Threat to the Market

Strict regulatory policies, along with large investment costs, will pose as major challenges to the allergy diagnostics market. Also, the highly consolidated nature of the market will obstruct growth of new entrants. Currently, the leading market players are working on the reduction of costs in order to tap more profit. However, a rise in the types of allergies over the coming years will fuel the demand for allergy diagnostics. Changing food habits among people worldwide, coupled with growing popularity of processed and packed foods, are expected to furnish significant opportunities, by the end of 2024.

The information presented in this review is based on a Transparency Market Research report, titled, “Allergy Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Hemophilia Treatment Drugs Market Trends, Regulatory Landscape and Operational Strategies 2024

The global hemophilia drug treatment market features an exceedingly consolidated vendor landscape, with the top three companies, namely Novo Nordisk A/S, Shire Plc., and Pfizer Inc., collectively accounting for a nearly 49% of the market in 2015, observes Transparency Market Research in a recent report. Focus on research and development activities aimed at the discovery of new drug candidates and strategic mergers and acquisitions with the view of expanding geographical reach and enhancing product portfolios are amongst the key strategies adopted by companies to beat competition.

Transparency Market Research estimates that the market will exhibit a promising 5.4% CAGR over the period between 2016 and 2024, rising from a valuation of US$15.8 bn in 2015 to US$25.1 bn by 2024.

This 188 page report gives readers a comprehensive overview of the hemophilia treatment drugs market. Browse through 36 data tables and 61 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/hemophilia-treatment-market.html

North America to Retain Position as Dominant Market for Hemophilia Treatment Drugs

Of the key hemophilia treatment drug varieties available in the global market, including desmopressin, plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, and antifibrinolytic agents, the segment of recombinant coagulation factor concentrates presently dominates. Their dominance is chiefly attributable to their low risk of causing blood-related infections. The segment is also poised to lead through the forecast period, acquiring nearly 47% of the overall market by 2024.

From a geographical perspective, the hemophilia treatment drugs market is presently the most lucrative and significant market for hemophilia treatment drugs, mostly owing to the high disposable incomes of patients and a well-established healthcare infrastructure. The region is likely to remain the leading contributor of revenue and business to the global hemophilia treatment drugs market on account of the presence of leading vendors and a rising population of hemophilia patients. The region is expected to acquire a nearly 41% of the global market by 2024.

Development of Novel Drugs Varieties to Drive Market

The rising prevalence of hemophilia is the primary driver of the global hemophilia treatment drugs market. Technological advancements in hemophilia drug innovation, along with the development of novel coagulating factors promising long-lasting clotting, are anticipated to contribute towards the growth of the market in the near future. An instance of one of the novel long-lasting clotting agents being developed is the drug emicizumab by Roche Pharmaceuticals.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving hemophilia treatment drugs market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1900

Clinical studies have demonstrated that people treated with emicizumab prophylaxis showed a statistically significant decline in the number of bleeds over a certain period as compared to people who received no prophylactic treatment. The demand for this type of treatment is expected to rise with time with rising consumer awareness about its benefits.

High Costs Restrain Sale of Drugs in Developing and Lesser-developed Economies

The high cost of hemophilia drugs is one of the key challenges hindering the overall development of the hemophilia treatment drugs market, especially across developing and lesser-developed economies. The market also faces the challenge of low diagnosis rate. Despite availability of generic testing for hemophilia, lack of awareness among patients restricts the potential patient base of the market, especially in remote parts of the world.

This review of the market is based on a recent market research report published by Transparency Market Research, titled “Hemophilia Treatment Drugs Market (Product - Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents; Disease Indication - Hemophilia A, Hemophilia B, Acquired Hemophilia, and Hemophilia C; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Point-of-care Diagnostics Market: Positive long-term growth outlook 2016 - 2024

The top four players cumulatively accounted for a little short of 80% of the global point-of-case diagnostics market in 2015, rendering its vendor landscape highly consolidated. The companies at the top Abbott Inc., Becton Dickinson & Co., Alere Inc., and F. Hoffmann-La Roche Ltd, finds Transparency Market Research (TMR) in a new study. “These companies boast a strong product portfolio, which has aided in their dominance,” said a leading TMR analyst. In the forthcoming years, the market is expected to witness the leading companies expanding their distribution network across India, China, Latin America, and Africa. These nations provide gigantic scope for the enterprises offering point-of-care diagnostic solutions as they witness a high prevalence of unmet medical needs.

This 176 page report gives readers a comprehensive overview of the point-of-care (PoC) diagnostics market. Browse through 24 data tables and 67 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/care-diagnostics-market.html

According to TMR, the global point-of-care diagnostics market will exhibit a CAGR of 6.9% between 2016 and 2024. At this pace, the market will reach US$11.7 bn by the end of 2024. Based on product, the demand for lateral slow assay stood out among other segments. By the end of 2024, the lateral slow assay segment is expected to hold nearly 38.3% of the global market. Regionally, Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa constituted the key market share. The global point-of-care diagnostics market is expected to witness the dominance of North America through the forecast period. By the end of 2024, the North America market is expected to hold a share of 38%.

Rising Incidence of Chronic Ailments Necessitating Point-of-care Diagnostics

The rising incidence of chronic ailments is a prime driver of the global point-of-care diagnostics market. As the need for curb prevalence of chronic diseases rise, the demand for automated diagnostics is expected to surge. The past few years have witnessed rising investment in the design and development of advanced point-of-care diagnostic kits to make patient care simpler and more accessible. This is expected to prove a positive spell, enabling strong growth in the global market.
Poor living choices are key reasons triggering the incidence of chronic ailments such as gastrointestinal diseases, cardiac ailments, hepatitis, cancer, respiratory and gastrointestinal diseases, and sexually transmitted diseases worldwide. Moreover, choosing unhealthy lifestyle patterns also cause medical conditions such as hypertension, obesity, and diabetes, which may require point-of-care diagnostics devices for round-the-clock monitoring. In addition, the prevalence of unmet medical needs across emerging nations in Asia Pacific and elsewhere will create growth opportunities for the market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving point-of-care (PoC) diagnostics market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1128

Inability to Screen Multiple Diseases at Ones Emerges as Key Drawback

According to the World Health Organization (WHO), nearly 14.1 million new cases of cancer was reported in 2012, which is expected to reach 15.5 million by the end of 2030. With this, experts also predict that market for point-of-care diagnostics is expected to get more expansive. Several diseases show symptoms, which demand precise testing by screening patients for multiple ailments. However, point-of-care diagnostics cannot screen multiple diseases at ones, which is one of its major drawbacks. Thus patients have continued to opt for laboratory testing so that they get accurate results.
While dynamic medical diagnostic kits have started offering qualitative results, they are yet to offer quantification of data. This leaves chances for inaccuracy of interpretation and can hamper treatments. Despite prolific research and development in point-of-care diagnostics, these kits offer approximation, which can result in misdiagnosis. These factors have emerged as key challenges, inhibiting the market’s trajectory.

This review is based on information derived from a TMR report, titled “Point-of-care Diagnostics Market (Product - Lateral Flow Assay Test, Flow-through Test, Solid Phase Assay Test, and Agglutination Assay Test; Application - Infectious Disease Test, Cholesterol Monitoring, Substance Abuse Test, Fertility and Pregnancy Test, and Blood Glucose Test; End Users - Hospitals, Clinics, Homecare Settings, and Diagnostic Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Drugs of Abuse Testing Market is Anticipated to Show the Robust Growth During 2016 - 2024

The top seven players in the global drugs of abuse testing market accounted for 63.7% in the market in 2015. The leading players Alere, Inc., F. Hoffmann La-Roche Ltd., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., Drägerwerk AG & Co. KGaA, Shimadzu Corporation, and Laboratory Corporation of America Holdings. Of these, Alere Inc. held a dominant share in the global market with its wide product portfolio for drugs of abuse testing, observes Transparency Market Research. “Companies are focused on ensuring organic and inorganic growth through acquisitions and development of new products,” states the lead author of this study.

According to the research report, the global drugs of abuse testing market is estimated to be worth US$6.4 bn by the end of 2024 as compared to US$4.1 bn in 2015. Between the forecast years of 2016 and 2024, the global market is expected to surge at a CAGR of 5.3%.

This 172 page report gives readers a comprehensive overview of the drugs of abuse testing market. Browse through 30 data tables and 83 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/drugs-abuse-testing-market.html

North America Shows Continued Growth in Global Drugs of Abuse Testing Market

In terms of geography, North America is projected to lead the global market as it estimated to rise at a CAGR of 5.7%. The growth of the North America drugs of abuse testing market will be attributable to the ever-growing demand for testing and screening all across the U.S. High level of awareness and efforts to ensure an efficient and safe working place is expected to keep the demand for these screening across the U.S. steady during the forecast period. Out of the various end users, the diagnostic laboratories are projected to lead with a CAGR of 5.3% between 2016 and 2024.

High Prevalence of Drug Abuse Augurs Well for Overall Market

The unfortunate and illicit consumption of drugs across the world has been the primary growth driver for the global drugs of abuse testing market. Rising incidences of substance abuse and its negative impact on the lives of abusers as well as those around them have forced governments and several non-profit organizations to take a stern stand against these harmful activities. Owing to this very reason, several hospitals, offices, diagnostic laboratories, and forensic laboratories are adopting various ways of testing for drug abuse. On-the-spot testing is also gaining traction in order to ensure random checks to reduce the incidence of mishaps due to abuse.

Presence of several clinical laboratories across the globe is yet another reason fueling the demand for drugs of abuse testing products. Growing number of hospitals that depend on laboratories are expected to boost the demand for products such as sample collection devices and analyzers. Furthermore, stringent norms at workplaces to ensure employees are not involved in drugs is expected to augment the demand for work place screening in the coming years. The skyrocketing number of deaths due to rising incidence of abuse of prescription drugs is estimated to drive the market as well.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving drugs of abuse testing market during 2016 - 2024: http://www.transparencymarketresearch.com/drugs-abuse-testing-market.html

Low Rate of Awareness in Developing Economies to Hamper Market

Though the global market has robust growth drivers, it is being tugged in the opposite direction by the lowering reimbursement rates. Poor reimbursement policies are likely to have a negative impact on the growth of the global drugs of abuse testing market. The market is also being restrained by the low rate of awareness in emerging economies of Asia Pacific, Latin America, and Africa. The high poverty and rampant abuse of drugs in these regions is anticipated to act as an impediment for overall market during the forecast period.

This review is based on Transparency Market Research’s research report, titled “Drugs of Abuse Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Hypertrophic Cardiomyopathy Therapeutics Market is Expected to Witness Highest Growth During 2015 - 2023

The global hypertrophic cardiomyopathy (HCM) therapeutics market is dominated by companies exhibiting high sales. However, generic manufacturers are making their presence felt in the market gradually. As per Transparency Market Research (TMR), the top three companies in the market, Sanofi S.A., Pfizer, Inc., and Merck & Co., accounted for a share of over 64.5%, which points toward a highly consolidated vendor landscape.

Intense competition exists among the top companies in the market. These enterprises are mainly focusing on expanding and differentiating their product portfolio to enjoy sustainable growth.

This 78 page report gives readers a comprehensive overview of the HCM therapeutics market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/hypertrophic-cardiomyopathy-therapeutics-market.html

Demand for HCM Therapeutics Surges due to Increasing Incidence of Congestive Heart Failure

“The prevalence of chronic cardiovascular ailments is fueling demand for effective treatment, which has been translating into lucrative sales opportunities for hypertrophic cardiomyopathy therapeutics,” said a lead TMR analyst. Heart diseases make one of the most common causes of death in both men and women around the world. According to TMR, the rising incidence of congestive heart failure considerably fuels demand for effective medications. This creates attractive opportunities for sales of hypertrophic cardiomyopathy therapeutics.

"Besides this, successful interventions conducted across several countries to spread awareness about hypertrophic cardiomyopathy have also aided the expansion of the HCM therapeutics market,” said the TMR analyst. Furthermore, patients are now more aware about the latest medical advances, which augurs well for the market. ECG screening is the most efficient technology for diagnosing HCM. The success demonstrated by this technology has significantly contributed in fuelling demand for HCM therapeutics.
Rising Penetration of Advanced Medical Devices to Threaten Market Growth

Despite witnessing positive growth opportunities, the rising penetration of medical devices such as pacemakers and defibrillators in the healthcare sector has been inhibiting the HCM therapeutics market’s trajectory. Demand for gene therapy and implantable medical devices is rising as patients gain adequate knowledge about positive results offered by such advanced medical devices. The increasing acceptance of these medical devices could limit the scope of expansion for the HCM therapeutics market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving HCM therapeutics market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7553

Nevertheless, drugs created specifically for the treatment of hypertrophic cardiomyopathy are yet to find approval. Once approved, this indication will bolster sales opportunities for the market players. Additionally, due to the high prevalence of unmet medical needs across Asia Pacific and the increasing medical expenditure in the region also boosts prospects for the HCM therapeutics market.
Regionally, North America holds the largest share in the global HCM therapeutics market. However, as per TMR, the market is also expected to witness strong growth in Asia Pacific and Rest of the World. The Asia Pacific HCM therapeutics market is poised to expand at 2.9% CAGR between 2015 and 2023. By drug class, the market was led by calcium channel blockers in 2014. By drug class, the calcium channel blockers is expected to dominate the market. It held over 37.4% of the HCM therapeutics market in 2014.

TMR estimates the overall value of the global hypertrophic cardiomyopathy therapeutics market at US$1.2 bn in 2014. Exhibiting a moderate CAGR of 1.4% from 2015 to 2023, the market is expected to reach US$1.3 bn by the end of 2023.

This review is based on information published by TMR, in a report titled “Hypertrophic Cardiomyopathy Therapeutics (HCM) Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 – 2023.”

Saudi Arabia Defibrillators Market: Dynamics and Opportunities Report by Transparency Market Research

The key players operating in the Saudi Arabia defibrillators market are HeartSine Technologies, Inc., Cardiac Science Corporation, Philips Healthcare, Physio-Control Inc., Schiller AG, and ZOLL Medical Corporation. These players are anticipated to focus on improving and assuring product quality to end users to build goodwill with products that are safer, observes Transparency Market Research in its latest research report. Companies will also endeavor to expand their market share by raising awareness about defibrillation through impactful promotional campaigns.

With these collaborative efforts of market players, the Saudi Arabia defibrillators market is expected to be worth US$49.8 mn by 2020 steadily rising at a CAGR of 8.3% from US$28.6 mn in 2013. The market will be driven by the ALS defibrillators segment as the opportunity in this product segment is anticipated to reach US$36.5 mn by 2020. An increasing adoption of ALS defibrillators in the ever-expanding healthcare sector has created a remarkable opportunity for this product segment over the past few years. However, the affordability of AEDs is expected to propel this segment as well.

This 70 page report gives readers a comprehensive overview of the Saudi Arabia defibrillators market. Browse through 05 data tables and 19 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/saudi-arabia-defibrillators-market.html

Hospitals Lead the Way with High Adoption of ALS

Amongst the end users, hospitals held a dominant share in the overall market as ambulances are the first point of contact in case of sudden cardiac arrest (SCA) in out-of-hospital settings. Furthermore, hospitals, being the primary caregivers, have a high adoption rate of ALS defibrillators as they facilitate monitoring of various health parameters at the same time. During the forecast period, the hospitals segment in the Saudi Arabia defibrillators market will reach a valuation of US$37.6 mn, expanding at a CAGR of 7.5% between 2014 and 2020.

Vernacular Medical Assistance Wins Hearts of End Users

Technologically advanced defibrillators that provide audio and video medical assistance in Arabic languages have boosted the overall market in recent years. As these machines require highly-skilled persons to operate them safely, the integration of vernacular language has enabled less-skilled professionals to also use these machines in a non-hospital setup. Features such as voice assistance have further increased the uptake of defibrillators across Saudi Arabia.

Initiatives taken by public and private medical organizations to safeguard human life have also worked in favor of this market. For instance, the installation of AEDs in aircraft and in religious places to resuscitate pilgrims in case of emergencies has given this market a substantial boost in the past few years.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Saudi Arabia defibrillators market during 2014 - 2020: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5867

Poor Regulatory Framework Hampers Market Growth

The lack of government interventions and supportive regulatory framework has hampered the sales of defibrillators across Saudi Arabia. The market is also being restrained by the poor collaboration between the public and private enterprises to raise awareness about defibrillators. Analysts predict that poor knowledge amongst overall population about sudden cardiac arrest and the importance of defibrillator and CPR has largely discouraged the overall market.

The expensive import duty that public hospitals, as well as private units, have to pay to own defibrillators has created a negative impact on the overall market. Furthermore, lack of interaction with the consumers and the poor branding and awareness campaigns are further dissuading the market growth.

“To stay ahead of the competition, players should focus on enhancing the quality of their products,” suggest the lead author of this research report. Integrating features such as remote patient monitoring and telemedicine are anticipated to be game-changing strategies for the players operating in the Saudi Arabia defibrillators market in the coming years. Furthermore, these features might also help by facilitating a prompt or a right line of treatment that paramedics should take in case of an emergency.
This review is based on Transparency Market Research’s report, titled “Saudi Arabia Defibrillators Market – Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 – 2020.”

Key Takeaways:

• Saudi Arabia defibrillators market poised to reach US$49.8 mn by 2020
• ALS defibrillators expand at a CAGR of 7.5% between 2014 and 2020
• Hospitals to become the dominant users of defibrillators over the forecast period

The Saudi Arabia Defibrillators market is segmented as follows:
Saudi Arabia Defibrillators Market, by Product

• Automated External Defibrillators
• Advanced Life Support Defibrillators

Saudi Arabia Defibrillators Market, by End User

• Hospitals
• Public Access Defibrillators
• Emergency Medical Services
• Business Workplace

Blood Transfusion Diagnostics Market Trends, Regulatory Landscape and Operational Strategies 2025

A recent intelligence study by Transparency Market Research (TMR) has detected that the global blood transfusion diagnostic market is highly fragmented in nature, owing to the participation of many local and regional players. As per the report’s findings, the top four companies didn’t even account for one-third of overall shares of the global blood transfusion diagnostics market in 2016. Apart from a few major companies, such as Immucor Inc., Ortho-Clinical Diagnostics, Inc., Bio-Rad Laboratories, Inc. Abbott Laboratories, Quotient, Ltd., BAG Health Care GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., and Hologic, Inc., most of the smaller players offer their products regionally and locally. Immucor Inc. currently accounts for the most prominent share in the global blood transfusion diagnostic market, at 11.6% in 2016, owing to its wide offerings in transfusion, transplant, and molecular diagnostics. Robust portfolio of products and solutions keeps Ortho-Clinical Diagnostics, Inc. in good stead in the global blood transfusion diagnostics market.

This 156 page report gives readers a comprehensive overview of the blood transfusion diagnostics market. Browse through 30 data tables and 83 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/blood-transfusion-market.html

As per the estimations of the TMR report, the demand in the global blood transfusion diagnostics market will increment at a healthy CAGR of 6.8% during the forecast period of 2017 to 2025, reaching a valuation of US$6.0 bn by the end of 2025, significantly up from its evaluated worth of US$3.3 bn in 2016. As far as recent market developments is concerned, Abbott Laboratories and St. Jude Medical, Inc., announced definitive agreement for Abbott to acquire St. Jude Medical, creasing a premier medical device leader with top positions and high growth worldwide. BAG Health Care GmbH launched a new BAGene kid and a new BAGene format to improve the results of its existing product BAGene SSP kit.

In terms of revenue, the kits and reagents segment of product type is anticipated to dominate the market during the forecast period, whereas application-wise, blood grouping is losing shares owing to technological advancements towards automation. Hospitals are expected to remain the most profitable end-users, by a long margin. Geographically, North America accounted for 43.1% share of the total market in 2016.

Escalating Blood Transfusion Procedures Driving Demand

Increasing number of blood transfusion procedures is the key factor augmenting the demand in the global blood transfusion diagnostics market. According to the American National Red Cross, approximately 21 million blood components are transferred in the U.S. each year. Over 90,000 people are affected by sickle cell disease in the U.S. and blood transfusion is a frequent process in sickle cell patients. In addition to that, the World Health Organization estimates that around 16 countries across the world have inadequate facilities for screening donated blood for one or more infections. This shortage is attributed to the irregular supply of test kits. Rapid technological advancement and automation in blood processing equipment, which can reduce the contamination risk associated with the collection and handling procedures, shortage of blood transfusion infrastructure in developing countries, increasing government awareness programs and incentives for blood transfusion and donation, and the development of the WHO recommended national blood policy.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving blood transfusion diagnostics market during 2017 - 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=23963

Low Blood Donation Rate Obstructing Market Prosperity

On the other hand, low blood donation rate and stringent regulation related to safe blood transfusion are a few hindrances faced by the global blood transfusion diagnostics market. The report observes that although blood donation is a remarkably safe medical procedure, lack of knowledge and beliefs obstructs potential blood donors from obliging. In addition to that, high investment and steep operational costs restrain emerging economies such as Brazil, India, China, and Indonesia from adopting new blood processing technologies. That being said, persistent awareness programs by various health organizations and government agencies is expected to somewhat overcome this restraint over the course of the forecast period.

The information presented in this review is based on a Transparency Market Research report, titled, “Blood Transfusion Diagnostics Market (Product Type - Kits & Reagents and Instruments; Application - Blood Grouping and Disease Screening (Molecular Disease Screening and Serological Disease Screening); Distribution Channel - Hospitals, Diagnostic Laboratories, and Blood Banks) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.”